Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo

The Randox Evidence Evolution runs on the company’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously, ensuring fast, accurate and reliable diagnosis.

Randox also launched a number of new tests on the Randox Biochip at this year’s AACC event, including a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in participants of pharmaceutical drug trials.

“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world. We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US,” said Randox managing director, Dr. Peter FitzGerald. “Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.”